Sep 09, 2021 / 03:00PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
Thanks for joining us for the [next] session. I'm Matthew Harrison, one of the biotech analysts here. I'm very pleased to have John Valliant and John Crowley from Fusion with us to start the next session. Before we get started, I just need to read a quick disclaimer statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at [morganstanley.com/researchdisclosures]
And with that, I'm going to turn it over to John Valliant to make some opening comments, and then we'll jump into Q&A.
John F. Valliant - Fusion Pharmaceuticals Inc. - Founder, CEO & Director
Thanks, Matthew. I appreciate the opportunity to chat with everyone and to be here with our Chief Financial Officer, John Crowley. I'm John Valliant, CEO of Fusion Pharmaceuticals and excited to be part of this rapidly growing field of radiopharmaceuticals in oncology. Fusion really kicked off in around
Fusion Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers